Released Nov 10, 2026, before the open
10-Q filed Nov 10, 2026, 41 days after period end · 0001628280-26-072495
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $132.00K | $173.00K | $109.00K |
| Net Income | -$20.78M | -$12.16M |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$14.01M |
| -$11.25M |
| EPS Diluted | — | — | -$0.20 | -$0.16 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Research and development expenses were $15.7 million for the quarter ended September 30, 2026, compared to $5.9 million for the same period in 2025, driven by OV329 and OV4071 study activities.¶2
Ovid reported a net loss of $20.8 million, or $0.10 per basic and diluted share, for the three months ended September 30, 2026, compared to a net loss of $12.2 million, or $0.17 per share, for the same period in 2025.¶3
Cash, cash equivalents and marketable securities totaled $161.4 million as of September 30, 2026, with expected financial runway into 2029.¶1¶4
Ovid expects to initiate a proof-of-concept study in TSC-associated seizures in the fourth quarter of 2026 and anticipates topline photosensitivity data in the first quarter of 2027.¶5¶6